ReviewPharmaceutics2022
Hyaluronic Acid-Based Nanomaterials Applied to Cancer: Where Are We Now?
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- From matrix to nucleus: CD44 as a central regulator of inflammaging, autophagy, and tissue homeostasis.Biogerontology · 2026Review
- Carbohydrate polymer-based biomaterials for light-triggered Photo-Immunotherapy: Design strategies, immune mechanisms, and translational outlook.Materials today. Bio · 2026Review
- Bio-based nanophotothermal systems as smart drug delivery platforms for multimodal synergistic cancer therapy-a review.Frontiers in medical technology · 2026Review
- Spectral Computed Tomography Diagnosis of Inflammatory Bowel Disease with Neodymium-Hyaluronic Acid Nanoparticles.Biomaterials research · 2026Article
- Enhanced Catalytic Cycle of Glucose Oxidation and Reactive Species with ROS and RHS Generation Mediated by Galvanic Engineering of Dual Atomic Sites on Covalent Organic Frameworks Demonstrating Synergistic Bimetal Tumor Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.Heliyon · 2025Article
- Effect of Photothermal Therapy Using Gold Nanoparticles Conjugated with Hyaluronic Acid in an Intracranial Murine Glioblastoma Model.International journal of nanomedicine · 2025Article
- Nanomaterials targeting cancer stem cells to overcome drug resistance and tumor recurrence.Frontiers in oncology · 2025Review
- How to Fabricate Hyaluronic Acid for Ocular Drug Delivery.Pharmaceutics · 2024Review
- Formulation, development and evaluation of hyaluronic acid-conjugated liposomal nanoparticles loaded with regorafenib and curcumin and their in vitro evaluation on colorectal cancer cell lines.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression.Cancers · 2024Review
- Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy.Frontiers in immunology · 2024Review
- Advances in Ferroptosis-Inducing Agents by Targeted Delivery System in Cancer Therapy.International journal of nanomedicine · 2024Review
- The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.International journal of molecular sciences · 2023Review
- Hyperbranched Polymers: Recent Advances in Photodynamic Therapy against Cancer.Pharmaceutics · 2023Review
- Nanomaterials for mRNA-based therapeutics: Challenges and opportunities.Bioengineering & translational medicine · 2023Review
- Size-Controllable Nanosystem with Double Responsive for Deep Photodynamic Therapy.Pharmaceutics · 2023Article
- Polysaccharide-Based Nanomedicines Targeting Lung Cancer.Pharmaceutics · 2022Review
- MRI Contrast Agents in Glycobiology.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Cancer cells normally develop the ability to rewire or reprogram themselves to become resistant to treatments that were previously effective. Despite progress in understanding drug resistance, knowledge gaps remain regarding the underlying biological causes of drug resistance and the design of cancer treatments to overcome it. So, resistance acquisition remains a major problem in cancer treatment. Targeted therapeutics are considered the next generation of cancer therapy because they overcome many limitations of traditional treatments. Numerous tumor cells overexpress several receptors that have a high binding affinity for hyaluronic acid (HA), while they are poorly expressed in normal body cells. HA and its derivatives have the advantage of being biocompatible and biodegradable and may be conjugated with a variety of drugs and drug carriers for developing various formulations as anticancer therapies such as micelles, nanogels, and inorganic nanoparticles. Due to their stability in blood circulation and predictable delivery patterns, enhanced tumor-selective drug accumulation, and decreased toxicity to normal tissues, tumor-targeting nanomaterial-based drug delivery systems have been shown to represent an efficacious approach for the treatment of cancer. In this review, we aim to provide an overview of some in vitro and in vivo studies related to the potential of HA as a ligand to develop targeted nanovehicles for future biomedical applications in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.